Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
P/B ratio for Bristol-Myers Squibb Company (BMY)
P/B ratio as of 2023: 3.61
According to Bristol-Myers Squibb Company's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.61. At the end of 2022 the company had a P/B ratio of 4.93.
P/B ratio history for Bristol-Myers Squibb Company from 1987 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.61 |
| 2022 | 4.93 |
| 2021 | 3.85 |
| 2020 | 3.70 |
| 2019 | 2.12 |
| 2018 | 6.05 |
| 2017 | 8.59 |
| 2016 | 6.04 |
| 2015 | 8.04 |
| 2014 | 6.59 |
| 2013 | 5.77 |
| 2012 | 4.00 |
| 2011 | 3.75 |
| 2010 | 2.89 |
| 2009 | 3.36 |
| 2008 | 3.76 |
| 2007 | 4.95 |
| 2006 | 5.16 |
| 2005 | 4.00 |
| 2004 | 4.88 |
| 2003 | 5.66 |
| 2002 | 5.16 |
| 2001 | 9.22 |
| 2000 | 15.07 |
| 1999 | 14.03 |
| 1998 | 16.71 |
| 1997 | 12.43 |
| 1996 | 7.93 |
| 1995 | 7.11 |
| 1994 | 4.92 |
| 1993 | 4.82 |
| 1992 | 5.46 |
| 1991 | 7.53 |
| 1990 | 6.13 |
| 1989 | 5.54 |
| 1988 | 4.55 |
| 1987 | 4.45 |